The EXPAND trial involved 1,651 people who took either siponimod or placebo capsules once a day for up to five years. A press release by Novartis, who make siponimod, announced that people on treatment took longer to show signs of progression than people on placebo. Progression was measured by EDSS scores taken every three months. Other measures used in the study, includes measuring progression with EDSS every six months, have not yet been made public.
Information for the study will be presented at the ECTRIMS meeting in London in September.
Linden Muirhead, the MS Trust's Director of Information & Engagment, said, "Research that shows it is possible to address MS progression is encouraging. We look forward to the publication of the full results to get a better idea of how this drug might benefit people with MS."